ArticleActa pharmaceutica Sinica. B2021
Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Ambroxol mitigates cyclophosphamide-induced liver injury by suppressing TLR-4/NF-κB signaling and oxidative stress and upregulating cytoglobin, TXNRD1 and HMGB1.World journal of gastroenterology · 2025Article
- Development and hepatotoxicity of rifamycin derivatives.Expert opinion on drug metabolism & toxicology · 2025Review
- Advancing hepatotoxicity assessment: current advances and future directions.Toxicological research · 2025Review
- Unveiling the Multifaceted Pharmacological Actions of Indole-3-Carbinol and Diindolylmethane: A Comprehensive Review.Plants (Basel, Switzerland) · 2025Review
- Amino Acid Hepatotoxicity Biomarkers in Human Hepatic Organoids: Promising Standardization of Drug Toxicity Evaluation.ACS pharmacology & translational science · 2025Article
- Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.Frontiers in immunology · 2025Article
- Signals of interstitial lung disease with novel antineoplastic agents in ovarian cancer: a three-database disproportionality study.Frontiers in pharmacology · 2025Article
- Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques.Cell & bioscience · 2024Review
- Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database.Heliyon · 2024Article
- In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.Clinical and translational science · 2024Article
- Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.Therapeutic advances in drug safety · 2024Article
- Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.Frontiers in pharmacology · 2024Article
- Risk Assessment of Psychotropic Drugs on Mitochondrial Function Using In Vitro Assays.Biomedicines · 2023Article
- Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune Diseases.Journal of personalized medicine · 2022Article
- Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.International journal of molecular sciences · 2022Review
- Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.Therapeutic advances in drug safety · 2022Article
- Hepatotoxicity Induced by Azole Antifungal Agents: A Review Study.Iranian journal of pharmaceutical research : IJPRReview
- Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, especially in idiosyncratic liver injury. This study examined liver injury reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) for drugs associated with hepatotoxicity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.